ZSAN Zosano Pharma Corporation

3.12
+0.05  (1.63%)
Previous Close 3.07
Open 3.19
Price To book 4.30
Market Cap 52.46M
Shares 16,815,000
Volume 9,148,890
Short Ratio 1.08
Av. Daily Volume 2,269,160

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial data due released February 13, 2017 - primary endpoints met.
M207
Migraine
Phase 2 data released September 2015. Considering Phase 3 initiation in 2016
ZP-Glucagon
Severe hypoglycemia

Latest News

  1. Biotech Industry Shaping up to Have a Breakout Year in 2017: Today's Reports on Insys Therapeutics and Zosano Pharma
  2. Zosano Pharma Corp (ZSAN) Is Playing With The Big Boys In The Migraine Space
  3. ZOSANO PHARMA CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  4. Can Zosano Pharma Turn Itself Around With This Late-Stage Migraine Trial Win?
  5. Fear of Missing Out Is Building
  6. Zosana Pharma's stock rockets after migraine patch produces positive trial results
  7. Zosano Pharma Announces 3.8mg Dose of M207, its Novel Transdermal Therapeutic, Meets Both Co-primary Endpoints in the ZOTRIP Pivotal Efficacy Trial in Migraine
  8. ZOSANO PHARMA CORP Files SEC form 8-K, Other Events
  9. Zosano Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
  10. Zosano Pharma Announces Last Subject Treated in its Migraine Pivotal Trial
  11. Zosano Pharma Announces Last Subject Treated in its Migraine Pivotal Trial
  12. Zosano Pharma Announces Sale of Non-Strategic Asset
  13. ZOSANO PHARMA CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  14. Zosano Pharma Announces Sale of Non-Strategic Asset
  15. ZOSANO PHARMA CORP Financials
  16. ZOSANO PHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
  17. Zosano Pharma Reports Third Quarter 2016 Financial Results
  18. Zosano Pharma Announces Completion of Enrollment in Pivotal Efficacy Trial for M207 for Acute Migraine
  19. ZOSANO PHARMA CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
  20. ZOSANO PHARMA CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard